Related Experiment Video

Updated: Jun 15, 2026

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma

Bhawna Sharma1, Seema Singh, Michelle L Varney

  • 1Department of Pathology and Microbiology, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, NE 68198-5900, USA.

Expert Opinion on Therapeutic Targets
|March 17, 2010
PubMed
Abstract

Insights

Targeting chemokine receptors CXCR1 and CXCR2 (CXCR1/2) offers a promising new therapeutic strategy for malignant melanoma. Blocking CXCR1/2 activity can inhibit melanoma growth, angiogenesis, and metastasis, addressing a critical need for effective treatments.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Malignant melanoma incidence is rising globally, with current systemic therapies showing limited survival benefits.
  • There is an urgent need for novel, targeted therapeutic strategies for melanoma treatment.

Purpose of the Study:

  • To review the targeting of chemokine receptors CXCR1 and CXCR2 (CXCR1/2) in malignant melanoma.
  • To discuss the rationale and future perspectives of CXCR1/2-targeted approaches.

Main Methods:

  • Overview of CXCR1/2 receptor roles in melanoma progression and metastasis.
  • Description of therapeutic strategies to block CXCR1/2 activation.

Main Results:

  • CXCR1 is constitutively expressed in all melanoma stages, while CXCR2 is found in aggressive tumors.
  • Modulation of CXCR1/2 impacts melanoma growth, angiogenesis, and metastasis.

Conclusions:

  • CXCR1/2 and their ligands are crucial in malignant melanoma pathogenesis.
  • Targeting CXCR1/2 represents a novel therapeutic avenue for malignant melanoma.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...